DUPIXENT blocks the signaling of two key sources of Type 2 inflammation (IL-4 and IL-13). This inflammation is an important
component in the development of asthma, eczema, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and
prurigo nodularis.

To learn more, explore our How DUPIXENT Works pages for your condition:

• Uncontrolled moderate-to-severe eczema (atopic dermatitis or AD) for ages 6+ months
• Add-on maintenance treatment for uncontrolled moderate-to-severe eosinophilic or oral steroid dependent asthma for
  ages 6+ years
  • DUPIXENT is not used to treat sudden breathing problems
• Add-on maintenance treatment for uncontrolled chronic rhinosinusitis with nasal polyposis (CRSwNP) for ages 18+ years
• Eosinophilic esophagitis (EoE) for ages 1+ years, who weigh at least 33 lb (15 kg)
• Prurigo nodularis (PN) for ages 18+ years